The combination of TGF-β blocking antibody and anti-PD-L1 reduced TGF-β signaling in stromal cells, facilitated T-cell penetration into the center of the tumor, and significantly restored anti-tumor immunity and suppressed tumor progression (Mariathasan et al., 2018). Here, TGFB1 is linked to neoplasm.